Key statistics
As of last trade Myriad Genetics Inc (0K3W:LSE) traded at 17.84, 5.39% above its 52-week low of 16.93, set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 17.84 |
Low | 17.84 |
Bid | -- |
Offer | -- |
Previous close | 17.84 |
Average volume | 2.06k |
---|---|
Shares outstanding | 90.82m |
Free float | 88.98m |
P/E (TTM) | -- |
Market cap | 1.58bn USD |
EPS (TTM) | -1.80 USD |
Data delayed at least 20 minutes, as of Nov 08 2024 15:24 GMT.
More ▼
Announcements
- Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
- Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
- Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
- Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
- Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
- Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
- Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
- Myriad Genetics to Host Investor Event on October 9, 2024
More ▼